– USA, CA – Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Dr. John Henderson (M.B., Ch.B.) as Chairman of the Board of Directors, effective April 8, 2022, succeeding Dr. Patrick Gage who resigns from the Board.
Additionally, the company also announced the appointment of Dr. Bob Harrington (M.D.) to its Board of Directors, effective today.
“We welcome John, another tenured member of our Board, to his new role as Chairman. John is well-suited to provide continuity of vision and disciplined oversight during the next period of transformation for our company. In addition, we are pleased to welcome Bob to our Board and look forward to his contributions and criticality of thought, considering his expertise having overseen dozens of global cardiovascular clinical trials aligned with our mission to improve patients’ lives,” said CEO, Robert Blum.
About Dr. John Henderson
Dr. Henderson has served as a member of the company’s Board since February 2009. Since December 2000, he has served as a consultant to the pharmaceutical industry. Before his retirement in 2000, Dr. Henderson was employed by Pfizer Inc. for more than 25 years and was most recently VP in the Pfizer Pharmaceuticals Group. He previously served as VP, Research & Development in Europe, and later Japan, as well as VP, Medical for Pfizer’s Europe, U.S., and International Pharmaceuticals groups.
About Dr. Robert A. Harrington
Dr. Harrington is a cardiologist and the Arthur L. Bloomfield Professor of Medicine and Chair of the Department of Medicine at Stanford University. Dr. Harrington was previously the Richard Sean Stack, MD Distinguished Professor and the Director of the Duke Clinical Research Institute at Duke University. He has served as a member of the American College of Cardiology Board of Trustees and is currently a member of the American Heart Association’s Board of Directors, its Science Advisory and Coordinating Committee, and a past President (2019-2020). He is an elected member of the Association of American Physicians and the Association of University Cardiologists. In 2015, he was elected to membership in the National Academy of Medicine/Institute of Medicine. In 2016, he was named a Master of the American College of Cardiology. He was awarded the AHA’s Clinical Research Prize in 2017.
Dr. Harrington earned a B.A. in English at the College of the Holy Cross and an M.D. from Tufts University School of Medicine.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused on diseases of muscle dysfunction and conditions of muscle weakness.
For more information: https://www.cytokinetics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.